---
title: "OptimizeRx appoints former J&J commercial data science chief Troy Sarich as adviser"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297777996.md"
description: "OptimizeRx has appointed Troy Sarich, former Chief Commercial Data Science Officer at Johnson & Johnson, as a company advisor. Sarich brings extensive experience in data, analytics, and AI across various therapeutic areas including cardiology and oncology. This appointment aims to support OptimizeRx's expansion of technology and data offerings for life sciences marketing."
datetime: "2026-09-02T11:31:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297777996.md)
  - [en](https://longbridge.com/en/news/297777996.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297777996.md)
generator: "portal-rs"
---

# OptimizeRx appoints former J&J commercial data science chief Troy Sarich as adviser

-   OptimizeRx appointed Troy Sarich as a company advisor. \* Sarich previously served as Chief Commercial Data Science Officer at Johnson & Johnson, focusing on data, analytics, and AI. \* His background includes roles spanning R&D and commercialization across cardiology, oncology, immunology, and neuroscience. \* The appointment supports OptimizeRx’s expansion of its technology and data offerings for life sciences marketing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020730PRIMZONEFULLFEED9819510) on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [OPRX.US](https://longbridge.com/en/quote/OPRX.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Analyst Reaffirms Buy on OptimizeRx, Citing Strong Second-Half Ramp and Intact 2027 Outlook](https://longbridge.com/en/news/300826902.md)
- [B. Riley Securities maintains Buy rating on OptimizeRx, $11 price target](https://longbridge.com/en/news/300460367.md)
- [Blue Owl maintains 5% tender cap on two BDCs amid elevated withdrawal requests](https://longbridge.com/en/news/300818386.md)
- [Constellation Brands Stock Forecast: Beer Demand Faces a Key Q2 Earnings Test](https://longbridge.com/en/news/300859275.md)
- [If I Could Only Buy 1 Space Stock for the Next Decade, It Wouldn't Be SpaceX or Rocket Lab](https://longbridge.com/en/news/300850222.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**